| Authors |
Váncsa, Szilárd ; Sipos, Zoltán ; Váradi, Alex ; Nagy, Rita ; Ocskay, Klementina ; Juhász, Félix Márk ; Márta, Katalin ; Teutsch, Brigitta ; Mikó, Alexandra ; Hegyi, Péter Jenő ; Vincze, Áron ; Izbéki, Ferenc ; Czakó, László ; Papp, Mária ; Hamvas, József ; Varga, Márta ; Török, Imola ; Mickevičius, Artautas ; Erőss, Bálint ; Párniczky, Andrea ; Szentesi, Andrea ; Pár, Gabriella ; Hegyi, Péter ; Imrei, Marcell ; Földi, Mária ; Miklós, Emőke ; Gódi, Szilárd ; Hágendorn, Roland ; Sarlós, Patricia ; Bajor, Judit ; Szabó, Imre ; Czimmer, József ; Faluhelyi, Nándor ; Farkas, Orsolya ; Kanizsai, Péter ; Nagy, Tamás ; Németh, Balázs ; Kui, Balázs ; Illés, Dóra ; Takács, Tamás ; Gajdán, László ; Vitális, Zsuzsanna ; Bod, Barnabás ; Novák, János ; Macarie, Melania ; Maurovich-Horváth, Pál ; Doros, Attila ; Deák, Pál Ákos ; Varga, Csaba ; Gaál, Szabolcs ; Zubek, László ; Gál, János ; Patai, Árpád ; Tornai, Tamás ; Lázár, Balázs ; Hussein, Tamás ; Kovács, Beáta ; Tarján, Dorottya ; Lipp, Mónika ; Urbán, Orsolya ; Emese, Fürst ; Edina, Tari |
| Abstract [eng] |
Introduction: Non-alcoholic fatty liver disease (NAFLD) is a proven risk factor for acute pancreatitis (AP). However, NAFLD has recently been redefined as metabolic-associated fatty liver disease (MAFLD). In this post hoc analysis, we quantified the effect of MAFLD on the outcomes of AP. Methods: We identified our patients from the multicentric, prospective International Acute Pancreatitis Registry of the Hungarian Pancreatic Study Group. Next, we compared AP patients with and without MAFLD and the individual components of MAFLD regarding in-hospital mortality and AP severity based on the revised Atlanta classification. Lastly, we calculated odds ratios (ORs) with 95% confidence intervals (CIs) using multivariate logistic regression analysis. Results: MAFLD had a high prevalence in AP, 39% (801/2053). MAFLD increased the odds of moderate-to-severe AP (OR = 1.43, CI: 1.09–1.89). However, the odds of in-hospital mortality (OR = 0.89, CI: 0.42–1.89) and severe AP (OR = 1.70, CI: 0.97–3.01) were not higher in the MAFLD group. Out of the three diagnostic criteria of MAFLD, the highest odds of severe AP was in the group based on metabolic risk abnormalities (OR = 2.68, CI: 1.39–5.09). In addition, the presence of one, two, and three diagnostic criteria dose-dependently increased the odds of moderate-to-severe AP (OR = 1.23, CI: 0.88–1.70, OR = 1.38, CI: 0.93–2.04, and OR = 3.04, CI: 1.63–5.70, respectively) and severe AP (OR = 1.13, CI: 0.54–2.27, OR = 2.08, CI: 0.97–4.35, and OR = 4.76, CI: 1.50–15.4, respectively). Furthermore, in patients with alcohol abuse and aged ≥60 years, the effect of MAFLD became insignificant. Conclusions: MAFLD is associated with AP severity, which varies based on the components of its diagnostic criteria. Furthermore, MAFLD shows a dose-dependent effect on the outcomes of AP. |
